MedImmune Message Board - Msg: 19517542

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (263)	11/19/2003 9:35:39 AM
From: IRWIN JAMES FRANKEL	of 416

Hi Tuck, >> This is already a fairly expensive drug to produce? Just asking, I don't know. In the recent CC on the reduced FluMist guidance the company commented on cost. They stated that at 10M doses the cost dropped to $10 per dose and at 20M the cost was $5 per dose. (I have no basis for comparison to other vaccines so I can't say that is expensive. Anyone know?) They also indicated that the flu vaccination market is 80-90M doses per year in the US. So there is room for much higher unit sales. I suspect that flu shot volumes are much higher for the elderly (FluMist stops at 50 years, I think) and so far they are not to get FluMist. They are also very cost sensitive. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next